Colgate-Palmolive heads into its third-quarter report with an unusual gap between what management says and what Wall Street believes. Three months ago the company raised its full-year earnings outlook to roughly $3.88 per share, near the top of its prior $3.73 to $3.91 range, and lifted its gross margin view to roughly flat after cutting it just one quarter earlier. Analysts have not fully bought in. The Street's full-year estimate sits at $3.81, noticeably below management's target, which suggests skepticism that the second half can absorb what the company itself called peak raw material and tariff pressure. Some of that gap may reflect differences in how one-time items are treated, but the direction of the doubt is clear.

For the September quarter, consensus calls for earnings of $0.92 per share on revenue of $5.33 billion. That implies sales growth of about 3.9% from last year's $5.13 billion but earnings growth of only about 1% from $0.91. In other words, analysts expect Colgate to sell more and keep little of it, a sign the Street is baking in margin compression from costs, a fading currency tailwind and the double-digit advertising increase management has been funding. Earnings are also expected to step down from the second quarter's $0.99. Full-year revenue consensus of $21.39 billion sits in the upper half of the company's $20.79 billion to $21.61 billion range, so the top line is not where the skepticism lives. The question is profitability.

That makes gross margin the single most important line in the release. The second-quarter improvement of about 100 basis points was driven mainly by revenue growth management, productivity savings and mix, not by a modest tariff refund. If those levers are structural, Colgate should be able to hold margins close to flat even as input costs crest. A result that shows gross margin roughly stable year over year would validate the raised outlook and make the $3.88 target look credible. A sharp reversal would suggest the second quarter was a high-water mark and would vindicate the more cautious estimates.

North America is the other pressure point. Shipments fell about 3% last quarter as retailers trimmed inventory, while consumption was roughly flat, and management acknowledged share losses, heightened competition and price gaps in select categories. Destocking eventually ends, so improving shipments that move back in line with consumption would be encouraging. Continued share erosion, or evidence that closing price gaps required heavier promotion, would be a warning that the U.S. problem is competitive rather than temporary. Management also signaled the second half would be more volume-led after price-heavy first-half gains, so volume trends in emerging markets like India, Brazil and Mexico, and at Hill's, which grew about 4% excluding private label, deserve close scrutiny. Early signs of traction from the Hill's fresh single-protein rollout in the U.S. would add texture to the growth story.

The organic sales guide is a quieter tell. Despite a 2.6% year-to-date pace, management declined to lift the low end of its 1% to 4% range, citing consumer volatility. Narrowing that range upward would signal genuine confidence; leaving it untouched again would read as continued caution.

Sentiment has cooled noticeably, with bearish readings rising to about 22% from roughly 8% ahead of the last report, and the stock's 2.8% gain since then trails the S&P 500 by a point. Yet shares at $93.40 sit comfortably above the 200-day average near $89 and within about 2% of the post-earnings high of $95.33, so a convincing margin story could push the stock toward a breakout. Ultimately, the report hinges on whether Colgate can show that its margin gains survive the cost peak. If they do, the Street's below-guidance estimates have room to rise; if not, management's raised outlook will start to look optimistic.